Menopause hormone therapy still remains a dominant
therapeutic modality in climacteric medicine. The core medical
skill is the ability to choose the optimal MHT preparation for
the given patient. Such choice is based on an understanding of
various clinical and metabolic effects of MHT depending on the
composition, dosage, and the method of application, this article discusses those choices.
This review summarizes studies related to anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition of ovarian cancer and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from.
A novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In this review, all available data is summarized, unanswered questions are highlighted, and pharmacological differences between each CDK4/6 inhibitor are discussed.
In the care of oncology patients, poly-ADP-ribose polymerase (PARP) inhibitors are best known as a semitargeted treatment
for BRCA1- and BRCA2-associated ovarian and breast cancers, this article reviews the broader understanding of PARP biology that has spurred interest in expanding their clinical utility.
